A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
about
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphomaThe mTOR signalling pathway in human cancerClinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated ReviewImmunotoxin - a new treatment option in patients with relapsed and refractory Hodgkin lymphomaTargeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignanciesCustomized targeted therapy in Hodgkin lymphoma: hype or hope?Protein kinase inhibitors against malignant lymphomaNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewAdvances in the treatment of relapsed or refractory Hodgkin's lymphomaJudicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and PerspectivesPembrolizumab in classical Hodgkin's lymphomaNovel CD20 monoclonal antibodies for lymphoma therapyHodgkin lymphoma, version 2.2015.A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategiesTargeted therapy in lymphoma.Hodgkin lymphoma.Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.The Management of Classical Hodgkin's Lymphoma: Past, Present, and FutureMulti-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphomaThe mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation.The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling.Recent Advances in the Development of Antineoplastic Agents Derived from Natural ProductsRelapsed Hodgkin lymphoma: management strategiesClinical response to everolimus in a patient with Hodgkin's lymphoma harboring a TSC2 mutationBrentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trialsSingle or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.From drug discovery to biomarker-driven clinical trials in lymphomaNovel treatment strategies for patients with relapsed classical Hodgkin lymphoma.Signal transduction inhibitor therapy for lymphoma.Predicting treatment outcome in classical Hodgkin lymphoma: genomic advancesUtility of mTOR inhibition in hematologic malignancies.Brentuximab vedotinTargeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.
P2860
Q24607479-3F6BC60C-3ADF-4F0B-898C-3E484FCDD6BBQ24627306-9D859566-9345-4A08-AF5C-FC94ACE4A5AEQ26770716-DF1BB1B7-A735-44FD-A201-2BD86F6DAC7FQ26772848-B814D289-73D9-43F9-B5DB-CB7BAA8D8514Q26829652-111A00F9-57A0-4945-B610-EEF76EE10D3BQ27002554-7F905CF2-8A3D-4595-8121-C9B062CEA278Q27024212-65A4B0F0-8642-4D87-83FE-3EB0A8EAE0C4Q27304386-071D0489-D713-4A25-8B88-85169C868824Q27694504-305EFAA0-BB03-4374-AC6C-651FC3A6E9E2Q28071388-5DDD3E8E-D66E-4680-8A69-5DC616FF3451Q28079273-4A06CA6F-CE23-4356-8620-34D4FAEC5A65Q28390112-AA811E04-E497-4871-8D82-4DE071BF6272Q30769157-31F165CD-B1CC-4FC8-9800-38497DBB440FQ33397302-B13EC5F9-E02D-4A01-9F9F-43509BDB463BQ33420273-17E3ACDB-DCB7-4F10-8A21-21F301526381Q33442755-8DC89781-0FD6-40B4-BCFB-5119B23D5B6AQ33704061-FAACDF90-9B98-4900-A9DB-AA3AB69507A4Q33886267-8157019E-0A90-4036-B686-2251D3B797A1Q34413686-3DD611FE-813B-4168-9B30-4D3F9C0EFF0AQ34643277-98D8F139-5479-4CEC-9C39-69ED6F2D13C0Q34732945-6EE621BA-269A-4BB7-BFC3-CEEBDC42ACD4Q35038852-662F2A63-D821-4181-8E6B-065DAA229134Q35525569-055A56CE-E9C4-4E94-894A-86F36DE4950DQ35705317-AB0D0502-0336-4883-BAED-A734C1A783A0Q35859219-30E0DD9C-8CB0-42FC-A109-2DDEBD518EC2Q35865599-5D062174-5462-415F-AB6C-533C6B8839DFQ35953399-A867911A-BB23-4ABB-A65A-105449DBBF6BQ36121394-654EEC9A-C7EA-427D-B63A-0D1AFF48BD64Q36273796-53DEE12E-4420-4AEC-89D2-7E507E159B9FQ37008427-51D77533-60DE-4B85-AA85-7032389BB060Q37027094-9B7A7342-77A8-492D-A600-2E61755AA59FQ37060652-1EBE8EEC-3A5A-4A97-B74C-583097B73485Q37216339-2E217906-E207-4A86-BDAA-FDABD72C7703Q37551148-CB09183D-2B7D-4E51-94C1-F8CA57933281Q37786716-7ACA245B-03F9-4453-80D1-7590D301B60CQ37829224-DBA96B63-7FEF-4116-9AD0-64EC13F2E12AQ37872044-8C1FE043-B82B-4616-9E4D-39065925C457Q37883723-C0D865DA-178C-4310-9A34-4F7FCC0D754DQ38017578-A8AAE11A-FED6-4224-8B43-C90A947A9037Q38218128-437F94E5-8AB5-4A0C-8131-92034B15C8E8
P2860
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
@ast
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
@en
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
@nl
type
label
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
@ast
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
@en
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
@nl
prefLabel
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
@ast
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
@en
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
@nl
P2093
P2860
P356
P1476
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
@en
P2093
Betsy R Laplant
Brian F Kabat
Craig B Reeder
David J Inwards
Ivana N Micallef
Joseph P Colgan
Luis F Porrata
Patrick B Johnston
Stephen M Ansell
Thomas E Witzig
P2860
P304
P356
10.1002/AJH.21664
P577
2010-05-01T00:00:00Z